Protagonist Therapeutics, Inc. (PTGX) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Newark, CA, United States. Der aktuelle CEO ist Dinesh V. Patel.
PTGX hat IPO-Datum 2016-08-11, 124 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Market, eine Marktkapitalisierung von $6.68B.
Protagonist Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing peptide-based therapeutic drugs for hematology, blood disorders, and inflammatory and immunomodulatory diseases. The company's clinical pipeline includes rusfertide (PTG-300), an injectable hepcidin mimetic in Phase II trials for polycythemia vera and hereditary hemochromatosis; PN-943, an oral integrin antagonist peptide in Phase II development for inflammatory bowel disease; and PN-235, an orally delivered interleukin-23 receptor antagonist for IBD and other indications. Protagonist maintains a license and collaboration agreement with Janssen Biotech, Inc. and operates from its headquarters in Newark, California.
